ReviewInternational journal of biological sciences2026
Natural Killer Cell Therapy in Ovarian Cancer: From Preclinical Potentials to Clinical Applications and Combination Strategies.
Review in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer represents a leading cause of mortality among gynecologic cancers, with limited therapeutic options for advanced and recurrent disease, highlighting an urgent need for innovative immunotherapies. Natural Killer (NK) cells, functioning as crucial effector cells of the innate immune system, have been identified as promising candidates for ovarian cancer treatment. This review systematically examines the evolving landscape of NK cell-based therapies for ovarian cancer, spanning their preclinical rationale, clinical translation, and innovative combination strategies. Nevertheless, the highly immunosuppressive tumor microenvironment (TME) of ovarian cancer and barriers to tumor infiltration pose significant challenges to their clinical efficacy. Here, we discuss various therapeutic strategies (such as cytokine-based agents, NK cell engagers and chimeric antigen receptor NK cells) designed to enhance NK cell activity, which leverage the unique characteristics of NK cells to complement standard treatments and potentiate combination immunotherapies. Ongoing preclinical and clinical investigations are paramount to converting these advances into efficacious therapies, ultimately revolutionizing the therapeutic paradigm for ovarian cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.